Quest Diagnostics (DGX) Liabilities and Shareholders Equity (2009 - 2026)

Quest Diagnostics has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $16.7 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $16.7 billion, up 5.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.1 billion (up 5.07% YoY), and the FY2025 annual result was $16.2 billion, changed 0.45% from the prior year.
• Liabilities and Shareholders Equity came in at $16.7 billion for Q1 2026 at Quest Diagnostics, up from $16.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $16.7 billion in Q1 2026 to a low of $12.8 billion in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $14.0 billion (2024), against an average of $14.6 billion.
• Across the five-year window, Liabilities and Shareholders Equity declined 5.69% in 2022 and rose 19.38% in 2024, its largest moves.
• Quest Diagnostics' Liabilities and Shareholders Equity stood at $12.8 billion in 2022, then advanced by 9.23% to $14.0 billion in 2023, then climbed by 15.2% to $16.2 billion in 2024, then increased by 0.45% to $16.2 billion in 2025, then advanced by 2.76% to $16.7 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $16.7 billion (Q1 2026), $16.2 billion (Q4 2025), and $16.2 billion (Q3 2025), per Business Quant data.